DERM
Price
$8.13
Change
+$0.17 (+2.14%)
Updated
Dec 24 closing price
Capitalization
220.61M
83 days until earnings call
Intraday BUY SELL Signals
ETON
Price
$16.99
Change
+$0.44 (+2.66%)
Updated
Dec 24 closing price
Capitalization
455.63M
76 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DERM vs ETON

Header iconDERM vs ETON Comparison
Open Charts DERM vs ETONBanner chart's image
Journey Medical
Price$8.13
Change+$0.17 (+2.14%)
Volume$29.52K
Capitalization220.61M
Eton Pharmaceuticals
Price$16.99
Change+$0.44 (+2.66%)
Volume$167.53K
Capitalization455.63M
DERM vs ETON Comparison Chart in %
DERM
Daily Signal:
Gain/Loss:
ETON
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DERM vs. ETON commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DERM is a StrongBuy and ETON is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (DERM: $8.13 vs. ETON: $16.99)
Brand notoriety: DERM: Notable vs. ETON: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: DERM: 16% vs. ETON: 63%
Market capitalization -- DERM: $220.61M vs. ETON: $455.63M
DERM [@Pharmaceuticals: Generic] is valued at $220.61M. ETON’s [@Pharmaceuticals: Generic] market capitalization is $455.63M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DERM’s FA Score shows that 0 FA rating(s) are green whileETON’s FA Score has 1 green FA rating(s).

  • DERM’s FA Score: 0 green, 5 red.
  • ETON’s FA Score: 1 green, 4 red.
According to our system of comparison, ETON is a better buy in the long-term than DERM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DERM’s TA Score shows that 4 TA indicator(s) are bullish while ETON’s TA Score has 5 bullish TA indicator(s).

  • DERM’s TA Score: 4 bullish, 4 bearish.
  • ETON’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, ETON is a better buy in the short-term than DERM.

Price Growth

DERM (@Pharmaceuticals: Generic) experienced а +4.77% price change this week, while ETON (@Pharmaceuticals: Generic) price change was +7.40% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.58%. For the same industry, the average monthly price growth was +8.11%, and the average quarterly price growth was +22.96%.

Reported Earning Dates

DERM is expected to report earnings on Mar 19, 2026.

ETON is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.58% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ETON($456M) has a higher market cap than DERM($221M). ETON has higher P/E ratio than DERM: ETON (124.00) vs DERM (39.08). DERM YTD gains are higher at: 107.928 vs. ETON (27.553). ETON has higher annual earnings (EBITDA): 703K vs. DERM (-685K). ETON has more cash in the bank: 37.1M vs. DERM (24.9M). DERM has less debt than ETON: DERM (25.3M) vs ETON (30.8M). ETON has higher revenues than DERM: ETON (70.3M) vs DERM (59.4M).
DERMETONDERM / ETON
Capitalization221M456M48%
EBITDA-685K703K-97%
Gain YTD107.92827.553392%
P/E Ratio39.08124.0032%
Revenue59.4M70.3M84%
Total Cash24.9M37.1M67%
Total Debt25.3M30.8M82%
FUNDAMENTALS RATINGS
DERM vs ETON: Fundamental Ratings
DERM
ETON
OUTLOOK RATING
1..100
2415
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4149
P/E GROWTH RATING
1..100
425
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DERM's Valuation (72) in the Biotechnology industry is in the same range as ETON (83) in the Pharmaceuticals Major industry. This means that DERM’s stock grew similarly to ETON’s over the last 12 months.

ETON's Profit vs Risk Rating (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for DERM (100) in the Biotechnology industry. This means that ETON’s stock grew somewhat faster than DERM’s over the last 12 months.

ETON's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as DERM (97) in the Biotechnology industry. This means that ETON’s stock grew similarly to DERM’s over the last 12 months.

DERM's Price Growth Rating (41) in the Biotechnology industry is in the same range as ETON (49) in the Pharmaceuticals Major industry. This means that DERM’s stock grew similarly to ETON’s over the last 12 months.

ETON's P/E Growth Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for DERM (42) in the Biotechnology industry. This means that ETON’s stock grew somewhat faster than DERM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DERMETON
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 19 days ago
88%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 17 days ago
86%
Bearish Trend 12 days ago
82%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
DERM
Daily Signal:
Gain/Loss:
ETON
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GVDNY79.470.19
+0.24%
Givaudan SA
BCNAF14.20N/A
N/A
Barco NV
CYVF74.75N/A
N/A
Crystal Valley Financial Corp.
PCWLF0.74N/A
N/A
PCCW Limited
XONI0.05N/A
-1.82%
Xtreme One Entertainment, Inc.

DERM and

Correlation & Price change

A.I.dvisor tells us that DERM and ETON have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DERM and ETON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DERM
1D Price
Change %
DERM100%
+2.14%
ETON - DERM
32%
Poorly correlated
+2.66%
CHRS - DERM
27%
Poorly correlated
+1.52%
AQST - DERM
26%
Poorly correlated
+1.70%
AMPH - DERM
25%
Poorly correlated
+1.36%
AVDL - DERM
23%
Poorly correlated
+0.19%
More

ETON and

Correlation & Price change

A.I.dvisor indicates that over the last year, ETON has been loosely correlated with MDGL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ETON jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ETON
1D Price
Change %
ETON100%
+2.66%
MDGL - ETON
34%
Loosely correlated
+0.10%
DERM - ETON
32%
Poorly correlated
+2.14%
VKTX - ETON
31%
Poorly correlated
+2.58%
LBTSF - ETON
30%
Poorly correlated
N/A
ARRY - ETON
30%
Poorly correlated
+2.10%
More